SYRE 32.76 Spyre Therapeutics, Inc.
| Range: | 8.43-47.97 | Vol Avg: | 483998 | Last Div: | 0 | Changes: | 1.48 |
| Beta: | 2.93 | Cap: | 1.46B | Currency: | USD | Exchange: | NASDAQ |
| Sector: | Healthcare | IPO: | Thu Apr 07 2016 | Empoloyees: | 50 | ||
| CUSIP: | CIK: | 0001636282 | ISIN: | US00773J2024 | Country: | US | |
| CEO: | Dr. Cameron Turtle DPHIL, Ph.D. | Website: | https://www.spyre.com | ||||
Spyre Therapeutics, Inc., a biotechnology company, focuses on advancing a pipeline of antibody therapeutics for the treatment of inflammatory bowel disease by combining antibody engineering, rational therapeutic combinations, and precision medicine approaches for patient selection. The company's pipeline includes extended half-life antibodies targeting a4ß7, TL1A, and IL-23. The company was formerly known as Aeglea BioTherapeutics, Inc. and changed its name to Spyre Therapeutics, Inc. in November 2023. Spyre Therapeutics, Inc. was founded in 2013 and is based in Waltham, Massachusetts.
Stock Details
SYRE 50
Baird Reiterates Outperform Rating on Spyre (SYRE)
Colleen Kusy·Thu Oct 17 2024
Robert W. Baird
SYRE 40
Wells Fargo Reiterates Overweight Rating on Spyre (SYRE)
Yanan Zhu·Tue Oct 15 2024
Wells Fargo
SYRE 40
Spyre Therapeutics price target raised to $40 from $32 at BTIG
Julian Harrison·Fri May 10 2024
BTIG
About The Monevue
The content provided on this site is for informational purposes only and does not constitute financial, investment, or professional advice. We are not registered investment advisors or financial planners, and we do not provide recommendations or advice on buying, selling, or holding any particular stocks or securities. Any investment decisions should be made based on your own research and consultation with a qualified financial professional. We are not responsible for any financial loss or damages incurred from reliance on the information provided on this site. Please invest responsibly and seek professional advice when needed.
• Powered by StackThrow